Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-693325.0%
operating margin TTM
-722275.0%
revenue TTM
6.78 Thousand
revenue per share TTM
0.0$
valuation ratios | |
|---|---|
| pe ratio | -0.87 |
| peg ratio | -0.22 |
| price to book ratio | 1.86 |
| price to sales ratio | 5,083.45 |
| enterprise value multiple | -1.63 |
| price fair value | 1.86 |
profitability ratios | |
|---|---|
| gross profit margin | -250.0% |
| operating profit margin | -722275.0% |
| pretax profit margin | -693325.0% |
| net profit margin | -693325.0% |
| return on assets | -125.23% |
| return on equity | -189.12% |
| return on capital employed | -221.69% |
liquidity ratio | |
|---|---|
| current ratio | 2.41 |
| quick ratio | 2.41 |
| cash ratio | 2.38 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 0.00 |
| days of payables outstanding | 26,514.64 |
| cash conversion cycle | -26,514.64 |
| receivables turnover | 0.00 |
| payables turnover | 0.01 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.00 |
| debt equity ratio | 0.00 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.00 |
| interest coverage | 0.00 |
| cash flow to debt ratio | 0.00 |
cash flow ratios | |
|---|---|
| free cash flow per share | -2.22 |
| cash per share | 2.12 |
| operating cash flow per share | -2.22 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | 0.00 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | -1,333.82 |
Frequently Asked Questions
When was the last time NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) reported earnings?
NeuroBo Pharmaceuticals, Inc. (NRBO) published its most recent earnings results on 07-11-2024.
What is NeuroBo Pharmaceuticals, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO)'s trailing twelve months ROE is -189.12%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. NeuroBo Pharmaceuticals, Inc. (NRBO) currently has a ROA of -125.23%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did NRBO's net profit margin stand at?
NRBO reported a profit margin of -693325.0% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is NRBO's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 2.41 in the most recent quarter. The quick ratio stood at 2.41, with a Debt/Eq ratio of 0.00.